Virological response and drug resistance 1 and 2 years post-partum in HIV-infected women initiated on life-long antiretroviral therapy in Malawi

AIDS Research and Human Retroviruses

Volumn 32, Issue 8, 2016, Pages 737-742

  Mancinelli, Sandro ^a   Galluzzo, Clementina Maria ^b   Andreotti, Mauro ^b   Liotta, Giuseppe ^a   Jere, Haswel ^c   Sagno, Jean Baptiste ^c   Amici, Roberta ^b   Pirillo, Maria Franca ^b   Scarcella, Paola ^a   Marazzi, Maria Cristina ^d   Vella, Stefano ^b   Palombi, Leonardo ^a   Giuliano, Marina ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c DREAM Program   (Malawi)

^d LUMSA UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMBINATION DRUG THERAPY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWI; POPULATION RESEARCH; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; BIOSYNTHESIS; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; GENETICS; GESTATIONAL AGE; GROWTH, DEVELOPMENT AND AGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUTATION; PREGNANCY; PREVENTION AND CONTROL; VERTICAL TRANSMISSION; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MALAWI; MUTATION; NEVIRAPINE; POSTPARTUM PERIOD; PREGNANCY; RNA, VIRAL; STAVUDINE; VIRAL LOAD;

EID: 84979986525     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0366     Document Type: Article

References (23)

1. World Health Organization: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Available at www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html (2013), accessed October 12, 2015
2. Tweya H, Gugsa S, Hosseinipour M, et al. Understanding factors, outcomes and reasons for loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi. Trop Med Int Health 2014; 19: 1360-1366
3. Tenthani L, Haas A, Tweya H, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (Oprion B+) in Malawi. AIDS 2014; 28: 589-598
4. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in lowincome, middle-income and high-income countries: A systematic review and a meta-analysis. AIDS 2012; 26: 2039-2052
5. Wadonda-Kabondo N, Bennet D, van Oosterhout JJ, et al. Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program. Clin Infect Dis 2012; 54: S362-S368
6. Kantor R, Smeaton L, Vardhanabhuti S, et al. Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virological failure: Results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis 2015; 60: 1541-1549
7. Boender TS, Hoenderboom BM, Sigaloff KCE, et al. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin Infect Dis 2015; 63: 1749-1758
8. Giuliano M, Andreotti M, Liotta G, et al. Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: Maternal and infant outcomes two years after delivery. PLoS One 2013; 8: e68950
9. Palombi L, Pirillo MF, Andreotti M, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: Drug concentrations, virological efficacy and safety. Antivir Ther 2012; 17: 1511-1519
10. Marazzi MC, Bartolo M, Emberti Gialloreti L, et al. Improving adherence to highly active antiretroviral therapy in Africa: The DREAM programme in Mozambique. Health Educ Res 2006; 21: 34-42
11. Sluis-Cremer N, Jordan MR, Huber K, et al. E138A in HIV-1 reverse transcriptase is more common in subtype C than B. Implications for rilpivirine use in resource-limited settings. Antiviral Res 2014; 107: 31-34
12. Palombi L, Galluzzo CM, Andreotti M. Drug resistance mutations 18 months after discontinuation of nevirapinebased ART for prevention of mother-to-child transmission of HIV in Malawi. J Antimicrob Chemother 2015; 70: 2881-2884
13. Wadondo-Kabondo N, Banda R, Moyo K, et al. Prevalence of transmitted HIV drug resistance among newly diagnosed antiretroviral therapy-naive pregnant women in Lilongwe and Blantyre, Malawi. Clin Infect Dis 2012; 54: S324-S327
14. Aghokeng AF, Monleau M, Eymard-Duvernay S, et al. Extraordinary heterogeneity of virological outcomes in patients receiving antiretroviral therapy and monitored with the World Health Organization approach in sub-Saharan Africa and Southeast Asia. Clin Infect Dis 2014; 58: 99-109
15. Zoufaly A, Jochum J, Hammerl R, et al. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. J Antimicrob Chemother 2015; 70: 922-925
16. Huntington S, Thorne C, Newell ML, et al. The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. AIDS 2015; 29: 2268-2278
17. Sha BE, Tierney C, Cohn SE, et al. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials 2011; 12: 9-23
18. Ngarina M, Kilewo C, Karlsson K, et al. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus study, Dar es Salaam, Tanzania. BMC Infect Dis 2015; 15: 175
19. Ruperez M, Pou C, Maculuve S, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother 2015; 70: 2639-2647
20. Hoffmann CJ, Cohn S, Mashabela F, et al. Treatment failure, drug resistance, and CD4 cell count decline among postpartum women on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2016; 71: 31-37
21. San Lio MM, Carboni R, Germano P, et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis 2008; 46: 1609-1616
22. Ryscavage P, Kelly S, Li JZ, Harrigan R, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother 2014; 58: 3585-3598
23. Luobet P, Charpentier C, Visseaux B, et al. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: A cross-sectional study. J Antimicrob Chemother 2015; 70: 1881-1884